Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

CPPHARM China

CP pharmaceutical group is a leading healthcare player in China. Stock listed in H. K. since 2000.
Website:
http://www.cppharm.com
Partnering Objectives
Headquartner in China
Yes
Qunrui Li
Deputy General Manager 

CR Sanjiu China

A leading Chinese listed company looking for cooperation opportunities in TAs such as oncology, orthopedics, CVS, respiratory, anti infection, orphan drugs, digestive and pediatric.
Website:
www.999.com.cn
Partnering Objectives
Headquartner in China
Yes
Vincent Liao
Senior Investment&BD manager 

CR999 China

one of the biggest pharmaceutics in china.
Website:
fly.999.com.cn
Partnering Objectives
Headquartner in China
Yes
秋霞 黄
投资项目经理 

Creacion Ventures China

Creacion Ventures is an USD fund of 150million, set up in 2020, focusing on investing cross border biotech companies. We spin off from 6 Dimensions.
Website:
NM
Partnering Objectives
Headquartner in China
No
Kathy Kang
associate 

Crinetics Pharmaceuticals United States

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Website:
https://crinetics.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Business Development
Headquartner in China
No
Biotech/Pharma Category
Mr. Greg Solis
Business Strategy Associate 
Functionality
Business Development

Crossject USA Inc United States

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.

Website:
www.crossject.com
Year of foundation
2001
Partnering Objectives
Headquartner in China
No
Assets Information 1
Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis. We also have a Medtech model where we can inject 0.2-0.7ml of your drug (small or large molecule) IM or SQ.
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1
needle free auto-injector
Medtech Development Stage
Don Zinn
VP US Business 
Functionality
Business Development

Crosswave Management United States

Seed and startup-scale investor focused on healthcare. Also provides cross-border partnering services.
Website:
crosswavemanagement.com
Partnering Objectives
Headquartner in China
No
Dr. Charles Hsu
Managing Partner 
Functionality
Investment

CRUise Lebanon

CRUise is the largest SMO Network in MEA region, we are aiming to have a network of clinical research units and Key Opinion Leaders interested in Clinical Research. CRUise will ensure the quality of research by having a network with unified international standards.

Website:
https://live.cruisemea.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Sharing CRUise concept with the attendees and having partners
Headquartner in China
No
Hadil Noureddine
Project Manager 
Functionality
Research and Clinical

CStone China

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
Website:
www.cstonepharma.com
Partnering Objectives
Headquartner in China
Yes
Ping Zhao
Greater China General Manager and Head of Commercial Operations 

CTS Capital China

CTS Capital was founded in 2017. As a private equity firm, CTS Capital focuses on investment opportunities in the biotechnology and healthcare services industries. CTS Capital is managed by a team of professionals with deep industry knowledge, extensive experiences in private equity and global strategic insights. Driven by our team’s business acumen and investment expertise, CTS Capital has made investments in companies at the cutting edge of the biotechnology and healthcare industries, including innovative drugs, medical devices, diagnostics, gene technology, digital health and AI in healthcare，etc.
We employ a research-driven investment approach and collaborate closely with our companies to build lasting and impactful businesses in the life sciences and healthcare industries. We are committed to working in close partnership with the top innovative pharmaceutical, biotech and medical technology companies to promote biotechnology innovation and healthcare transformation in China.
Website:
http://www.ctsfunds.com/
Company Size (Fulltime employees)
11-50
Year of foundation
2017
Partnering Objectives
Please specify your partnering goal
Looking for clients and partners in Pharmaceutical,Biotechnology,Medical Devices and Sevices
Headquartner in China
Yes
Mr. Song Zhang
CEO 
Functionality
Investment